In Vitro: Ac-PLVE-FMK can efficiently inhibit the activity of Cat-B and Cat-L in the target-based assay (human recombinant enzymes) . Ac-PLVE-FMK can penetrate the cell membrane in the cell-based assay on two human renal cancer cell lines (769-P and A498) .